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Abstract
Purpose To study if second-generation antipsychotic (S-GA) use during the first trimester of pregnancy is associated with 
an increased risk of major congenital malformations (MCM).
Methods A population-based birth cohort study using national register data extracted from the Drugs and Pregnancy 
database in Finland, years 1996–2017. The sampling frame included 1,273,987 pregnant women. We included singleton 
pregnancies ending in live or stillbirth or termination of pregnancy due to severe malformation. Pregnancies with exposure 
to known teratogens were excluded. Women were categorized into three groups: exposed to S-GAs (n = 3478), exposed to 
first-generation antipsychotics (F-GAs) (n = 1030), and unexposed (no purchases of S-GAs or F-GAs during pregnancy, 
n = 22,540). We excluded genetic conditions and compared the prevalence of MCMs in S-GA users to the two comparison 
groups using multiple logistic regression models.
Results Use of S-GAs during early pregnancy was not associated with an increased risk of overall MCMs compared to 
unexposed (adjusted odds ratio, OR 0.92; 95% CI 0.72–1.19) or to F-GA users (OR 0.82; 95% CI 0.56–1.20). Of individual 
S-GAs, olanzapine use was associated with an increased risk of overall MCMs (OR 2.12; 95% CI 1.19–3.76), and specifi-
cally, an increased risk of musculoskeletal malformations (OR 3.71; 95% CI 1.35–10.1) when compared to unexposed, while 
comparisons to F-GA users did not show significant results.
Conclusions Olanzapine use is associated with an increased risk of major congenital malformations and specifically, mus-
culoskeletal malformations. Use during pregnancy should be restricted to situations where no safer alternatives exist.
Keywords Pregnancy · Second-generation antipsychotics · Major congenital malformations
Introduction
Maternal well-being is important for a successful pregnancy 
outcome, and psychiatric illness must be treated adequately 
also during pregnancy. The clinician is often encountered by 
this dilemma, optimizing between effective maternal drug 
treatment and fetal safety. While antipsychotics are pri-
marily used for psychotic illnesses, the second-generation 
antipsychotics (S-GAs) are also used in bipolar disorder for 
mood stabilization and in unipolar depression together with 
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antidepressants [1]. Further, off-label use includes use in 
anxiety disorders, obsessive–compulsive disorders (OCD), 
post-traumatic stress disorder (PTSD) and insomnia [2].
The use of S-GA has been steadily increasing among 
pregnant women since year 2000; a recent study from ten 
countries reported that up to 2% of pregnant women use 
S-GAs, while there are differences across countries [3]. At 
the same time, the use of first generation antipsychotics 
(F-GA) has waned [3, 4]. The increasing use of S-GAs may 
be at least partly explained by the increasing off-label use of 
quetiapine for insomnia [2, 5].
Previous studies have not observed an association 
between F-GA or S-GA use and an increased risk of overall 
congenital malformations [6–8]. For the individual S-GAs, 
most data are available for aripiprazole, olanzapine, que-
tiapine and risperidone. Of these, only risperidone use has 
been associated with a small increased risk of congenital 
malformations and specifically, a marginally increased risk 
of congenital heart defects [6, 8]. While very few data are 
available for other organ specific malformations, no specific 
associations have been reported [9]. However, teratogens 
typically affect organ differentiation specifically, based on 
their pharmacodynamic and biological effects; an increased 
risk of organ specific malformations may therefore remain 
undetected when malformations are analyzed all together as 
a group [8, 10].
We evaluated the risk of overall major congenital mal-
formations (MCM) and organ specific MCMs in offspring 
exposed to S-GAs in early pregnancy using national regis-
ter data. Comparisons were made to unexposed and those 
exposed to F-GAs, controlling for maternal illness.
Methods
Data source and study cohort
This is a population-based birth cohort study using national 
register data extracted from the existing Drugs and Preg-
nancy database, established by the Finnish Institute for 
Health and Welfare (THL), the Social Insurance Institu-
tion of Finland (Kela), and the Finnish Medicines Agency 
(FIMEA). This database enables continuous surveillance 
of drug safety during pregnancy and includes data from the 
Medical Birth Register, the Abortion Register, the Register 
of Congenital Malformations, and the Prescription Regis-
ter, including also the Special Refund Entitlement Register. 
Data from the different registers have been linked by the 
personal identification number assigned to all citizens and 
permanent residents in Finland. Data from births and ter-
minations of pregnancy, and prescription drug purchases 
have been collected since January 1, 1996, and data in our 
study extend until December 31, 2017. In the database, 
beginning of pregnancy has been calculated from the best 
clinical estimation of gestational age at birth, primarily 
based on ultrasound. First trimester is defined as extend-
ing from the last menstrual period (LMP) until 84 days 
gestation.
More detailed information on the registers included have 
been published previously [4] and are also available in the 
Supplementary material.
Definition of exposed and unexposed cohorts
The study frame included 1,273,987 pregnancies ending 
in livebirth, stillbirth or elective termination of pregnancy 
due to fetal malformation (Fig. 1). We included 1,235,950 
singleton pregnancies. Pregnancies exposed to known tera-
togens (Supplementary Table S1) during 3 months before 
pregnancy until end of pregnancy (n = 9876) were excluded 
from the study (Fig. 1).
Exposed to S‑GAs Women who purchased S-GAs (olanzap-
ine, quetiapine, risperidone, aripiprazole, clozapine, ziprasi-
done, sertindol, or asenapine; Supplementary Table S2) dur-
ing 1 month before pregnancy until the end of first trimester 
(n = 3478).
Unexposed Women had no S-GA or F-GA purchases during 
three months before pregnancy until end of first trimester. 
Controls in this group were matched for year of birth of child 
and were randomly selected as five controls for one S-GA or 
F-GA exposed (5:1) (n = 22,540).
Exposed to F‑GAs Women who purchased F-GAs (Supple-
mentary Table S2) during one month before pregnancy until 
the end of first trimester but did not purchase S-GAs during 
the same time period. Pregnancies exposed only to prochlor-
perazine, often used for morning sickness, (n = 392) were 
excluded. This comparison group was included to control 
for maternal psychiatric illness (n = 1030).
Major congenital malformations
The outcomes of interest were overall MCMs, i.e., infant/
fetus with at least one major congenital malformation 
and organ-specific malformations, including cardiovas-
cular (ICD-9 diagnoses 745–747), central nervous system 
(ICD-9; 740–742) respiratory tract malformations (ICD-
9; 748), orofacial clefts (ICD-9; 7490–7492), urogenital 
(ICD-9; 752,753), gastrointestinal malformations (ICD-
9;  750,751, 7566), and musculoskeletal malformations 
(ICD-9; 7543–7548, 755). We excluded genetic conditions 
from the analyses (Fig. 1).
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Covariates
Covariates included maternal sociodemographic and medical 
characteristics and use of other medication, categorized as 
shown in Supplementary Table S3. Data on pre-pregnancy 
BMI are partially available beginning from 2004 and for all 
women from September 2005. Alcohol use is not routinely 
collected in the MBR and could therefore not be included in 
analyses.
Statistical analyses
All data in the Drugs and Pregnancy database are pseu-
donymized. We made a descriptive analysis on demographic 
differences between study cohorts. We also calculated the 
prevalence of overall MCMs and organ-specific malforma-
tions in the S-GA group, the unexposed group, and the F-GA 
group, and further, on the level of individual S-GAs.
We used logistic regression to assess the association 
between S-GA use during preconception or first trimes-
ter and MCMs in comparison with unexposed and F-GA 
exposed pregnancies. First, pattern of missingness for soci-
oeconomic status, smoking, cohabitation pre-pregnancy 
BMI, and parity was explored as appropriate. The major-
ity of missingness was driven in one missing value either 
in socio-economic status or BMI. Incomplete records were 
assumed to be missing at random, and we used multiple 
imputation by chained equations (MICEs) to predict missing 
values in covariates to improve measurement of prognos-
tic factors [11, 12]. Imputation models included outcome 
variables, exposure variables, covariates and also auxiliary 
variables that correlated or were believed to be associated 
with missingness (birth weight, gestational age, number of 
drug purchases and hospital district). We created 20 imputed 
data sets of which estimates were combined using Rubin’s 
rules [13, 14].
The crude models included adjustment for year of deliv-
ery. For the adjusted analyses, clinically relevant and plau-
sible covariates were first tested for association with the 
three-class exposure status. When associated with expo-
sure at significance level P < 0.1, the covariate was further 
tested separately for association of outcome. We included 
in the final logistic regression models covariates which 
were associated with exposure and outcome at P < 0.1 as 
potential confounders (Supplementary Table S4). An infant/
fetus with multiple organ-specific MCMs contributed to 
each malformation subgroup. All analyses were performed 
using SAS Enterprise Guide 7.1(SAS Institute Inc., Cary, 
NC, USA).
The utilization of sensitive health register data for scien-
tific research and the data linkages in the Drugs and Preg-
nancy project have been approved by the register adminis-
trators and the national data protection authority. Since the 
study subjects are not contacted, according to the Finnish 
legislation informed consent is not required. The study was 
registered in The European Network of Centres for Pharma-
coepidemiology and Pharmacovigilance (ENCePP) register 
before data collection started (EUPAS4799). The study has 
been granted the ENCePP seal, following the ENCePP prin-
ciples of standards, transparency and independence of good 
pharmacoepidemiology practice throughout the research 
process (www. encepp. eu).
Fig. 1  Flow chart of the expo-
sure and outcome information 
used in the study
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Results
Overall, 4508 (0.4%) pregnant women with a singleton preg-
nancy (N = 1,235,950) used antipsychotics during the first 
trimester or 30 days before pregnancy, and 3478 (0.3%) used 
S-GAs. The number of stillbirths and ETOPFAs were small 
across the exposure groups (Fig. 1).
Maternal characteristics of the three study groups are pre-
sented in Supplementary Table S3. S-GA users were more 
likely to be overweight than F-GA users or unexposed and 
S-GA and F-GA users were more likely to smoke tobacco 
than women in the unexposed group. Pre-gestational diabe-
tes and gestational diabetes were significantly more common 
among the S-GA users compared to F-GA users and to the 
unexposed group.
The numbers of excluded infants/fetuses with genetic con-
ditions are presented in Fig. 1. Of the individual S-GAs, the 
most commonly used was quetiapine (n = 2618), followed 
by olanzapine (n = 413), risperidone (n = 242), aripiprazole 
(n = 220), and clozapine (n = 106).
The prevalence and risk of overall MCMs are presented 
in Tables 1 and 2. Compared to unexposed, the risk did not 
differ between any S-GA users and unexposed (Table 1). Of 
the individual S-GAs, olanzapine use was associated with a 
twofold increased risk of MCMs (odds ratio, OR 2.12; 95% 
CI 1.19–3.76) after full adjustment to confounders.
The risk of MCMs in any S-GA users was lower than 
in the F-GA group; however, this difference was not sta-
tistically significant (Table 2). Of the individual S-GAs, 
olanzapine use was associated with an increased risk of any 
MCM when compared to F-GA users, but did not reach sta-
tistical significance.
Use of any S-GA was not associated with an increased 
risk of any organ specific malformations when compared 
to unexposed or to the F-GA group (Tables 3 and 4). Of 
the individual S-GAs, olanzapine use was associated with 
Table 1  Prevalence and risk 
of overall major congenital 
malformations in pregnancies of 
second-generation antipsychotic 
users. Comparisons to the 
unexposed
Analyses based on imputed data
S-GA second-generation antipsychotic
* Adjusted for year of delivery; **Adjusted for year of delivery, maternal age at delivery, parity, pre-preg-
nancy BMI, cohabitation, smoking, SES, other psychiatric drugs, psychotic and other severe mental disor-
ders, pre-gestational diabetes, gestational diabetes
Statistically significant results written in bold
Exposure Prevalence 
1/1000
Crude OR* 95% CI Adjusted** OR 95% CI
Unexposed 43.7 Ref Ref Ref Ref
Any S-GA 54.1 1.20 1.02–1.41 0.92 0.72–1.19
Quetiapine 49.3 1.07 0.88–1.29 0.85 0.64–1.12
Olanzapine 79.9 1.90 1.33–2.73 2.12 1.19–3.76
Risperidone 53.7 1.29 0.73–2.26 1.48 0.75–2.90
Aripiprazole 72.7 1.60 0.96–2.68 1.80 0.74–4.42
Clozapine 37.7 0.88 0.32–2.41 2.00 0.30–13.35
Table 2  Prevalence and risk 
of overall major congenital 
malformations in pregnancies of 
second-generation antipsychotic 
users. Comparisons to first-
generation antipsychotic users
Analyses based on imputed data
S-GA second-generation antipsychotic, F-GA first-generation antipsychotic
* Adjusted for year of delivery; **Adjusted for year of delivery, maternal age at delivery, parity, pre-preg-
nancy BMI, cohabitation, smoking, SES, other psychiatric drugs, psychotic and other severe mental disor-
ders, pre-gestational diabetes, gestational diabetes
Exposure Prevalence 
1/1000
Crude OR* 95% CI Adjusted** OR 95% CI
Any F-GA 58.9 Ref Ref Ref Ref
Any S-GA 54.1 0.88 0.60–1.29 0.82 0.56–1.20
Quetiapine 49.3 0.80 0.52–1.24 0.76 0.49–1.18
Olanzapine 79.9 1.40 0.84–2.32 1.33 0.78–2.27
Risperidone 53.7 0.89 0.47–1.71 0.83 0.42–1.61
Aripiprazole 72.7 1.38 0.68–2.79 1.06 0.50–2.24
Clozapine 37.7 0.67 0.23–1.92 0.51 0.16–1.57
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a nearly fourfold increased risk of musculoskeletal malfor-
mations when compared to unexposed (OR 3.71; 95% CI 
1.35–10.1). Compared to F-GA users, the risk of musculo-
skeletal malformations was higher but the association did 
not remain statistically significant (Table 4). The muscu-
loskeletal malformations recorded among the olanzapine 
exposed infants/fetuses were various and no pattern of mal-
formations was observed.
Discussion
In this study based on national register data, use of second-
generation antipsychotics during early pregnancy was not 
associated with an increased risk of overall major congeni-
tal malformations compared to unexposed pregnancies or to 
pregnancies where the woman used first-generation antipsy-
chotics. Of the individual S-GAs, olanzapine use was associ-
ated with a twofold increased risk of overall malformations, 
and specifically, a nearly fourfold increased risk of mus-
culoskeletal malformations when compared to unexposed.
Use of S-GAs has been increasing among the preg-
nant population [3, 4] and indications for S-GA use have 
expanded during the last decade to include also illnesses out-
side psychotic disorders [3, 5]. S-GAs are used increasingly 
in treating bipolar disorder and as augmentation treatment 
in unipolar depression [15]. Further, S-GAs may be pre-
ferred during pregnancy because of safety concerns related 
to antiepileptic drugs as mood stabilizers [3]. Antipsychotic 
augmentation may also be effective in treatment-refractory 
OCD [16]. Present guidelines state that there is insufficient 
evidence to recommend for or against antipsychotic medi-
cation for PTSD [17] and use should be restricted to situa-
tions where symptoms have not responded to other drug or 
psychological treatments [18]. However, a European study 
reported that nearly 60% of more than 1,000 patients with 
a diagnosis of PTSD were prescribed antipsychotics, most 
commonly quetiapine, olanzapine and risperidone [19]. Fur-
ther, a population-based study from Norway suggested that 
the majority of quetiapine prescriptions during 2004–2015 
were for indications other than psychosis [5]. S-GAs and 
particularly quetiapine are used off-label for anxiety disor-
ders and sleep disturbances with little evidence to support 
use for insomnia [20, 21]. There are no data about S-GA use 
during pregnancy and specific indications.
Our finding that S-GAs as a group do not increase the 
risk of congenital malformations is in line with most previ-
ous studies. A prospective follow-up study including more 
than 500 pregnancies following first trimester exposure to 
S-GAs and including also pregnancy terminations reported 
an increased risk of overall malformations in S-GA users 
when compared to unexposed (OR, 2.13; 95% CI, 1.19–3.83) 
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and the authors concluded that the results likely resulted 
from detection bias [9]. No increased risk of congenital 
malformations was observed in a cohort study based on 
health administrative databases in Canada and including 
approximately 1,000 S-GA exposed pregnancies ending in 
birth, applying high dimensional propensity score matching 
analyses [7]. Also, the largest study based on Medicaid data 
including more than 9,000 pregnancies exposed to S-GAs 
and ending in live birth did not observe an increased risk of 
overall (OR 1.05; 95% CI 0.96–1.16) or cardiac (OR 1.06; 
95% CI 0.90–1.24) malformations in the fully adjusted, pro-
pensity score-based analysis. Of the individual drugs, only 
risperidone use (> 1500 pregnancies) was associated with 
an increased risk of overall malformations (OR 1.26; 95% 
CI 1.02–1.56) and a marginally significant risk of cardiac 
malformations (OR 1.26; 95% CI 0.88–1.81) [6]. No sign 
of teratogenicity has been reported for aripiprazole, que-
tiapine, or olanzapine; the number of reported olanzapine 
exposed pregnancies analyzed for malformations totals close 
to 3,000 pregnancies [6, 8, 22]. Contrary to these findings, 
olanzapine use in our study was associated with a substan-
tially increased risk of overall malformations and specifi-
cally with musculoskeletal malformations when compared 
to the unexposed cohort.
The association of olanzapine use with an increased risk 
of overall malformations was unexpected, given the reas-
suring data from the previous studies [6–8]. Very few data 
exist for other specific malformations than congenital car-
diac defects. It is possible that an increased risk of organ 
specific malformations (other than cardiac defects) may have 
remained undetected in studies which have focused on the 
overall malformation risk. Olanzapine has not been terato-
genic in animal studies.
One study based on prospectively collected data in rela-
tion to outcome reported no major differences in organ 
specific malformations, including musculoskeletal mal-
formations in S-GA users compared to F-GA users or to 
pregnancies with no exposure but the total number of S-GA 
exposed pregnancies available for analyses was only 430, 
and no results were reported for individual S-GAs [9]. S-GA 
treatment may cause disturbances in glucose metabolism, 
leading to hyperglycemia and diabetes, and poor glycemic 
control before pregnancy and in early pregnancy is associ-
ated with an increased risk of congenital malformations [23, 
24]. Typical malformations related to maternal hypergly-
cemia include cardiovascular and central nervous system 
malformations, but also musculoskeletal malformations [23, 
25]. While impaired glucose metabolism is a common side 
effect of all S-GAs, one would expect to find an increased 
malformation risk associated with any S-GA use and also 
with each individual S-GA. However, olanzapine of the 
S-GA drug group has the highest diabetogenic properties 
[26] and could therefore differ from the other S-GAs in its 
teratogenic potential. If our findings were related to maternal 
hyperglycemia, it is difficult to explain why previous stud-
ies have not shown an association between olanzapine use 
and an increased risk of overall congenital malformations or 
cardiac malformations. Maternal hyperglycemia is also an 
unlikely explanation, as we adjusted for pregestational and 
gestational diabetes in the analyses for overall malforma-
tions, and for pregestational diabetes in the analyses of organ 
specific malformations,
The discrepant findings compared to previous research might 
even be related to genetic differences in drug metabolizing 
enzyme activity across populations. Olanzapine is metabolized 
by hepatic glucuronidation and by cytochrome P450 (CYP) 
1A2 and to a minor extent by CYP 2D6 -mediated oxidation 
to inactive metabolites. Ethnic differences exist for both CYP 
enzymes but CYP 1A2 activity does not differ significantly 
between the Finnish population and other Caucasians popula-
tions [27]. Further, the findings related to the impact of CYP1A2 
and UDP-glucuronosyltransferase (UGT) 1A4 variants on olan-
zapine steady-state concentrations have been conflicting [28, 
29]. The genetic profile of CYP2D6 in the Finnish population 
differs from North European populations in that the frequency 
of the ultrarapid metabolizer genotype is higher and that of poor 
metabolizer is lower in the Finnish population [30]. However, 
CYP2D6 polymorphism appears to have no significant influence 
on olanzapine pharmacokinetics [28, 29]. No further conclu-
sions related to pharmacogenetic differences can be made as we 
had no genetic information on the subjects.
The risk of overall and musculoskeletal malformations 
in olanzapine exposed pregnancies was not statistically 
significantly increased when compared to F-GA users, 
suggesting that maternal illness or illness-related factors 
may have contributed to the findings. However, the risk 
estimates for olanzapine in these comparisons—even if 
not statistically significant -were strikingly different from 
the other S-GAs, showing a risk increase of round 30% for 
both overall and musculoskeletal malformations, while 
the risk estimates for other S-GAs were below or close 
to one.
Our study has several strengths. First, we included a 
comparison group of women exposed to F-GAs, control-
ling for maternal illness. Second—and contrary to previous 
studies—we included pregnancy terminations due to fetal 
malformation, which is important as more than 10% of all 
pregnancies where the fetus has been diagnosed with a major 
malformation are currently terminated [31]. Third, the reim-
bursement register includes 99% of all reimbursed medi-
cations [32], and the National Medical Birth Register data 
have been validated and are considered good [33]. Further, 
the data sources included in our study allowed for extensive 
control of potential confounders.
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The limitations are those typical for studies using large 
administrative databases and national register data. Exposure 
misclassification may occur if the woman does not take her 
medication even if she bought it in the pharmacy, moving 
the risk estimate towards one if the drug was a teratogen. 
However, antipsychotic drugs are generally prescribed for 
psychotic conditions needing drug treatment and their use 
continues in a relatively constant manner from preconcep-
tion through first trimester [34]. Residual confounding is 
an unlikely explanation to our findings as one would expect 
residual confounding to affect the results of all individual 
S-GAs and not only olanzapine.
We conclude that olanzapine use in early pregnancy is 
associated with an increased risk of overall malformations, 
and specifically musculoskeletal malformations. Until these 
results are either confirmed or refuted, use of olanzapine 
should only be used in pregnancy when no safer alterna-
tives exist.
Supplementary information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00228- 021- 03169-y.
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